---
document_datetime: 2025-11-05 10:44:40
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mektovi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mektovi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0727535
conversion_datetime: 2025-12-30 08:52:19.541928
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Mektovi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                      |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------|
| Variation type II /  | This was an application for a variation | 18/09/2025                          |                                             | SmPC and PL                      | SmPC new text Braftovi SmPC section 4.2: For |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000241083   | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.2 and 5.2 of the SmPC in order to update paediatric information following PIP compliance check (EMEA-C- 001588-PIP01-13- M03 and EMEA-C- 001454-PIP03-15-M03). In addition, the took the opportunity to implement a   | MAH minor correction   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|

<div style=\"page-break-after: always\"></div>

| doses and dose reductions for the management of     |
|-----------------------------------------------------|
| adverse reactions result in plasma exposure similar |
| to that achieved in adults: • Weighing 40 kg        |
| and more: the adult dose 45 mg BID with the same    |
| dose reduction: 30 mg BID. • Weighing less          |
| than 40 kg: 30 mg BID, based on the simulations at  |
| lower doses, no dose reduction is proposed,         |
| Children under 12 years should not be treated with  |
| binimetinib. For more information, please refer to  |
| the Summary of Product Characteristics.             |